Table 8.
No Difference in OS and RR between CT+Cetuximab vs. CT Alone in Asian Subgroup
EGFR-TKIs, epidermal growth factor receptor tyrosine-kinase inhibitors; OS, overall survival; RR, response rate.
Small sample size (n=121, 10% of total) and difference in histology and post-study EGFR-TKI treatment do not allow to draw definitive conclusions.